You are here

  • Home
  • Archive
  • Volume 18, Issue 3
  • A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer

Article metrics

Article menu
Download PDFPDF
Original Article
A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer

 

Online download statistics by month:

Online download statistics by month: March 2019 to April 2024

AbstractFullPdf
Mar 20191002
Apr 20193901
May 20192200
Jun 20191400
Jul 20191600
Aug 20192401
Sep 20191800
Oct 20191900
Nov 20193501
Dec 20192900
Jan 20202801
Feb 20201902
Mar 2020900
Apr 20201000
May 20202801
Jun 20202200
Jul 20201300
Aug 2020800
Sep 20201400
Oct 20201101
Nov 2020600
Dec 2020600
Jan 20211400
Feb 2021200
Mar 20212200
Apr 2021500
May 2021601
Jul 2021100
Sep 2021100
Oct 20212301
Nov 2021600
Dec 20212100
Jan 20221802
Feb 2022800
Mar 20221902
Apr 20222100
May 20223600
Jun 20224002
Jul 20224500
Aug 20225000
Sep 20223600
Oct 20224900
Nov 20224800
Dec 20222800
Jan 20233600
Feb 20237300
Mar 20231000
May 20231100
Jun 20231001
Jul 20231201
Aug 20231000
Sep 2023600
Oct 20234100
Nov 2023900
Dec 20231900
Jan 20241400
Feb 20241800
Mar 2024400
Apr 20241300
Total1185020